摘要
Thi Thanh Phuong NGUYEN 医师
皮肤科医师
Multimodal therapy for corticosteroid-induced rosacea-like dermatitis
Objectives: To explore the rationale and clinical efficacy of a multimodal treatment strategy in managing corticosteroid-induced rosacea-like dermatitis.
Introduction: Corticosteroid-induced rosacea-like dermatitis (CIRD) induced by prolonged or inappropriate use of topical corticosteroids presents a therapeutic challenge due to its chronic inflammation, skin barrier disruption, vascular changes and patient hypersensitivity. Multimodal therapy has emerged as an effective approach to address the complex pathophysiology of this condition.
Materials / method: This approach integrates anti-inflammatory agents, skin barrier repair formulations, vascular changes and microbiome-modulating therapies; including topical anti-inflammatory agents (e.g., calcineurin inhibitors, metronidazole), barrier-repair moisturizers, systemic agents such as low-dose doxycycline and topical probiotics. In addition, vascular-targeted lasers (e.g., pulsed dye laser) and EBDs (e.g., intense pulsed light – IPL) are employed to reduce persistent erythema, telangiectasia, and inflammation. These technologies also contribute to skin rejuvenation and microbiome modulation.
Results: Multimodal therapy has demonstrated significant improvements in symptom control, reduced flare frequency, and enhanced skin tolerance. Early corticosteroid withdrawal, patient education, and tailored regimens based on disease severity are critical to therapeutic success.
Conclusion: A comprehensive multimodal treatment strategy offers a safe and effective pathway for managing corticosteroid-induced rosacea-like dermatitis, addressing both symptom relief and long-term skin health restoration.
披露 - Thi Thanh Phuong NGUYEN
> 您是否获得了任何资金来支持您关于这个主题的研究?
不是
> 您在这项研究工作中是否获得过任何酬金、报酬或其他形式的补偿?
不是
> 您是否与任何可能与您研究中涉及的药物、材料或器械存在激烈竞争的实体有任何财务关系?
不是
> 您是否拥有或已申请过与您研究中所讨论的仪器、药物或材料相关的任何专利?
不是
这项工作没有任何直接或间接的资金支持。由作者自己承担责任。
Published on 2025年 7月 28日 - Recorded during IMCAS Asia 2025